Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
This combination tablet brings together Olmesartan Medoxomil, a selective angiotensin II receptor blocker (ARB), and Chlorthalidone, a thiazide-like diuretic, for effective control of high blood pressure. Olmesartan lowers blood pressure by blocking angiotensin II at AT1 receptors, preventing vasoconstriction and promoting vascular relaxation. Chlorthalidone enhances the antihypertensive effect by promoting sodium and water excretion from the kidneys, reducing plasma volume and vascular resistance. Compared to Hydrochlorothiazide, Chlorthalidone provides a longer duration of action, making it suitable for 24-hour blood pressure control. The fixed-dose combination of 20 mg Olmesartan with 12.5 mg Chlorthalidone is often prescribed to patients whose hypertension is not adequately managed with monotherapy or who require a potent combination to achieve target blood pressure levels. This dual-acting therapy significantly reduces the risk of long-term cardiovascular complications such as heart attack, stroke, and chronic kidney disease.
Common side effects include dizziness, headache, fatigue, and mild gastrointestinal discomfort. Chlorthalidone may cause increased urination, electrolyte imbalances (low potassium, sodium, or magnesium), mild dehydration, and increased uric acid levels. Olmesartan can occasionally cause hypotension, particularly in volume-depleted patients. Rare side effects include kidney function changes, allergic reactions, or photosensitivity. Regular monitoring of blood pressure, kidney function, and serum electrolytes is recommended during treatment.
Olmesartan Medoxomil 20 mg + Chlorthalidone 12.5 mg Tablet is indicated for the management of essential hypertension in adults, especially in patients requiring combination therapy to achieve optimal blood pressure targets or those unresponsive to a single-agent treatment.
This medication should be used under medical supervision only. It is contraindicated in pregnancy, particularly during the second and third trimesters, due to the risk of fetal injury or death. Caution is advised in patients with kidney or liver impairment, severe dehydration, or electrolyte disturbances. Avoid combining with potassium supplements or potassium-sparing diuretics unless prescribed. Alcohol intake should be minimized, as it can enhance the blood pressure-lowering effect. The medicine is not recommended during breastfeeding. Do not discontinue the therapy abruptly without consulting a healthcare provider. Regular follow-up visits and lab monitoring are essential to ensure safety and effectiveness.
Store the tablets in a cool, dry place below 30°C. Protect from moisture, heat, and direct sunlight. Keep out of the reach of children and pets. Do not use the medication after the expiry date.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Composition : Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 20 mg + Chlorthalidone 12.5 mg Tablet is a combination antihypertensive medication used for the management of high blood pressure (hypertension). It combines Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), with Chlorthalidone, a thiazide-like diuretic that helps reduce excess fluid and sodium in the body. This dual mechanism provides strong and sustained blood pressure control, making it an important product in the cardiology and cardiovascular care segment with high demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. Combination antihypertensive therapies are widely prescribed for better BP control, ensuring steady prescriptions, repeat orders, and long-term market stability, making it a strong addition to any cardiovascular portfolio.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription volume, long-term patient adherence, increasing prevalence of hypertension, and continuous institutional demand, making this product a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.